Status:
UNKNOWN
Therapeutic Monitoring of Infliximab and Adalimumab
Lead Sponsor:
IRCCS Burlo Garofolo
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
1-17 years
Brief Summary
Anti tumor necrosis factor (TNF agents), particularly infliximab and adalimumab, changed the way chronic inflammatory bowel disease (IBD) refractory to conventional therapies is treated, including in ...
Detailed Description
Anti-TNF agents, particularly infliximab and adalimumab, changed the way chronic inflammatory bowel disease (IBD) refractory to conventional therapies is treated, including in pediatric patients. Thes...
Eligibility Criteria
Inclusion
- IBD subjects
- age between 0 and 17 years
- suitable for treatment with infliximab or adalimumab
Exclusion
- Pediatric subjects with IBD not suitable for treatment with infliximab or adalimumab
Key Trial Info
Start Date :
March 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06033469
Start Date
March 15 2018
End Date
June 30 2024
Last Update
June 14 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Maggiore
Bologna, Italy
2
Ospedale Ca' Foncello
Treviso, Italy
3
IRCCS Burlo Garofolo
Trieste, Italy, 34137